Rockwell Medical, Inc. (RMTI) compared with its closest peers (DMAC, ABEO, IMRX, IRD, VNDA). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $351.06M | -11.4 |
| Abeona Therapeutics Inc. (ABEO) | $347.67M | 5.2 |
| Immuneering Corporation (IMRX) | $342.90M | -5.2 |
| Opus Genetics, Inc. (IRD) | $336.11M | -2.5 |
| Vanda Pharmaceuticals Inc. (VNDA) | $318.12M | -2.4 |
| Cartesian Therapeutics, Inc. (RNAC) | $294.84M | -1.4 |
| Entrada Therapeutics, Inc. (TRDA) | $294.65M | -3.0 |
| Fulcrum Therapeutics, Inc. (FULC) | $291.46M | -9.6 |
| Turn Therapeutics Inc. (TTRX) | $282.84M | -33.6 |
| CAMP4 Therapeutics Corporation (CAMP) | $280.51M | -2.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
RMTI overview · RMTI earnings · RMTI financials · RMTI KPIs · RMTI investor relations · RMTI ownership · RMTI filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.